CSIMarket
 
Protara Therapeutics Inc   (TARA)
Other Ticker:  
 
 
Price: $4.2100 $0.13 3.186%
Day's High: $4.41 Week Perf: 3.69 %
Day's Low: $ 3.97 30 Day Perf: 113.71 %
Volume (M): 85 52 Wk High: $ 4.42
Volume (M$): $ 356 52 Wk Avg: $2.43
Open: $4.14 52 Wk Low: $1.04



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Protara Therapeutics Inc
Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapies to treat rare and specialty diseases. The company is dedicated to improving the lives of patients by providing innovative treatment options. Protara Therapeutics Inc utilizes a targeted approach to identify and develop drug candidates, with a particular emphasis on rare diseases with significant unmet medical needs. The company's goal is to bring these therapies to market and make a meaningful impact on patient outcomes.


   Company Address: 345 Park Avenue South New York 10010 NY
   Company Phone Number: 844-0337   Stock Exchange / Ticker: NASDAQ TARA
   TARA is expected to report next financial results on March 07, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Protara Therapeutics Presents Encouraging Phase 1a ADVANCED-1 Trial Data and Unveils Study Design for ADVANCED-2 Trial at SUO Meeting

Published Thu, Nov 30 2023 1:31 PM UTC



Protara Therapeutics, a clinical-stage company focused on developing transformative therapies for cancer and rare diseases, has recently announced additional promising data from the Phase 1a dose-escalation component of its ongoing ADVANCED-1 clinical trial. The data relates to TARA-002, the company's investigational cell-based therapy for treating high-grade non-m...

Protara Therapeutics Inc

Protara Therapeutics Inc Faces $-10.7 Million Operating Shortfall, Raising Concerns for Future Growth



Protara Therapeutics Inc, a clinical-stage company focusing on developing transformative therapies for cancer and rare diseases, recently released its financial results for the third quarter of 2023. While the revenue remained unchanged, the company experienced a notable operating shortfall. This article aims to examine the latest developments in Protara Therapeutics' fiscal period and shed light on the impact it may have on the company's future prospects.
Operating Shortfall:
During the period between July and September 2023, Protara Therapeutics faced an operating shortfall of $-10.7 million. This represents an increase from the previous year's shortfall of $-7.691 million, indicating potential challenges for the company. It can be inferred that the company's expenses exceeded its earnings during this period.

Protara Therapeutics Inc

Protara Therapeutics Displays Disturbing Deterioration in Fiscal Behavior; Reports Staggering $12.14 Million Loss in Q2 2023


Introduction
As the earnings cycle for fiscal April to June 2023 unfolds, several companies have recently disclosed their financial results. Among these companies operating in the Biotechnology & Pharmaceuticals sector, Protara Therapeutics Inc has come under the spotlight. With a reported operating loss of $12.14 million for the fiscal interval ending June 30, 2023, the company faces the pressure to diversify its business model to mitigate the growing concerns of shareholders and investors.
Shrinking Productivity Improvement at Protara Therapeutics
In the midst of its latest earnings cycle, Protara Therapeutics has witnessed a decline in productivity improvement. Shareholders and investors appear to be less interested in this particular aspect, as they await additional business strategies from the company. Acknowledging this lackluster performance, Protara's CEO is actively pursuing distinct financial plans and exploring new product lines to boost the company's prospects.

Protara Therapeutics Inc

Protara Therapeutics Inc Reports Steady Revenue but Operating Deficit in 1Q 2023, Provides Promising Outlook for Future Growth

Investors in Protara Therapeutics Inc, a biotech company focused on developing innovative treatments for rare and serious diseases, were pleased to see that the company's revenue remained steady during the fiscal January to March 31 2023 period. However, they were paying close attention to the company's operating deficit, which came in at $-9.732 million during the same period.
Despite this operating deficit, many analysts see this as a promising development, and a good sign for the future of the company. In fact, compared to the same period in the previous year, the company had managed to reduce its operating deficit from $-10.874 million. This improvement has given many analysts confidence in the company's potential.
Although Protara Therapeutics Inc is still developing its business model, the company managed to cut its diminishing returns in the fiscal period ending March 31 2023 to $-9.045 million, from $-10.755 million in the first quarter of 2022. These figures showed progress towards improving the company's financial position, and this is good news for investors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com